Abstract 49P
Background
Glioblastoma (GBM) remains one of the most lethal brain cancers. CAR T cells targeting IL13Rα2 have shown tumour shrinkage and extended survival in some patients, but challenges remain, such as sustaining T-cell activity and overcoming the tumour microenvironment (TME). Here we show a new “armoured” CAR T (NS007) to better tackle the immunosuppressive TME and enhance persistence in solid tumours.
Methods
We developed a highly specific humanized single-domain antibody (VHH) targeting IL13Rα2. Human T cells were engineered using a single retroviral vector encoding a fourth-generation CAR with 4 additional elements: - 1) A component that blocks TGF-beta signalling - 2) A constitutive receptor that drives cellular proliferation - 3) an engineered single-chain IL-12 -4) a suicide gene for controlled cell elimination. These armoured CAR-T cells NS007, were evaluated for their cytolytic capacity against IL13Rα2-expressing cancer cells and ability to counteract immunosuppression both in vitro and in vivo.
Results
NS007 outperformed non-armoured CAR T cells, exhibiting greater tumour cell destruction, better proliferation, and longer persistence. In co-cultures, NS007 cells were less sensitive to TGF-β-mediated suppression, while also activating bystander NK and T cells via an attenuated IL-12. Furthermore, the engineered IL-12 showed no toxicity in syngeneic mouse models. The suicide gene, activated by an FDA-approved drug (Trastuzumab Emtansine), successfully eliminated NS007 cells both in vitro and in vivo. NS007’s efficacy, survival, and safety were confirmed in an aggressive orthotopic U87-MG GBM model using ultra-low doses (<10000 cells).
Conclusions
Our enhanced single cassette CAR T-cell design demonstrates key improvements: - enhanced tumour-killing capacity - resilience against TGF-β - extended persistence in the host - Ability to activate the host innate immune system through an attenuated cytokine - Ability to be turned off through the activation of a suicide gene These advancements represent a significant step forward in addressing challenges associated with CAR T-cell therapy in solid tumors, particularly for GBM treatment.
Legal entity responsible for the study
Chimeris UK.
Funding
Chimeris UK.
Disclosure
M. Mangolini, S. Srivastava, E. Souster, Y. Yang, R. Karatill, L. Schultz, B. Ma, D. Pombal, S. Cordoba, S. Onuoha: Financial Interests, Personal, Stocks/Shares: Chimeris Uk. A. Ramon, M. Greenig, P. Sormanni: Financial Interests, Personal, Advisory Role: Chimeris Uk.
Resources from the same session
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session